This is part of MetLife’s plan to expand access to new and differentiated health services for customers in Asia to help them better understand and manage their risk of serious illnesses like cancer and determine the best prevention and treatment options.
The HCC BoostUp Rider, attached to the HealthCare Choice Rider, gives customers coverage for a combination of medical benefits including genomic testing for cancer, out-patient dengue treatment, home nursing care, and pre-hospitalisation treatment.
Joyce Au-Yeung, regional head of health for MetLife in Asia, said: “We’re pleased that AmMetLife, is the first insurer to offer a genomic tumour assessment benefit for cancer patients in Malaysia, so they have more information to undertake precision treatment.
“We already offer genomic testing and precision medicine benefits through some of our solutions in China and pharmacogenomics benefits as a value-added service in Korea.”
To ensure its services and solutions keep up with medical trends and customers’ evolving needs, MetLife has teamed up with medical experts like Dr Steven Tucker, who specialises in cancer, genomics and precision medicine.
Across Asia, MetLife has launched a combination of holistic insurance solutions and services to help customers better understand how to prevent, diagnose, treat and manage serious illness.
In doing so, the company is focused on the five serious illnesses most relevant to Asians: cancer; cardiovascular disease; diabetes; dementia; and mental health.
Au-Yeung added: “Our ambition is to help customers in Asia increase the number of healthy years they live by providing access to differentiated services to help prevent, diagnose, treat, and manage these conditions.”
AmMetLife offers a range of life assurance and wealth protection solutions distributed through a combination of over 200 AmBank and AmMetLife branded branch offices.